ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0425

Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases
Abstract Number: 0489

Use of Chair Sit-to-Stand as a Pragmatic Alternative to Assess Frailty in Rheumatoid Arthritis
Abstract Number: 0435

Use of Contraception in Women of Childbearing Age with Immune-Mediated Rheumatic Diseases: Experience from an Italian Centre
Abstract Number: 1929

Use of Digital Health Tools for Health Promotion Among Individuals with Rheumatologic Diseases in the United States
Abstract Number: 0742

Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab
Abstract Number: 1925

Use of Geocoded Social Deprivation Indices to Understand Health Disparities in Pediatric Rheumatology
Abstract Number: 1984

Use of ICD Codes for the Identification of Patients with Immune Checkpoint Inhibitor Induced Inflammatory Arthritis
Abstract Number: 0201

Use of Infrared Thermography for Expedited Rheumatology Referral in a Primary Care Center
Abstract Number: 0503

Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Abstract Number: 0456

Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis
Abstract Number: 2276

Use of Methotrexate and TNF-α Inhibitors in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease: A Survey of Rheumatologists
Abstract Number: 2459

Use of Nailfold Capillaroscopy as a Predictor of Cardiovascular Events and Mortality in Systemic Sclerosis
Abstract Number: 0134

Use of Oral Contraceptives in Females with Rheumatoid Arthritis Is Not Associated with an Increased Risk of Venous Thromboembolism: United Kingdom-population Based Study
Abstract Number: 0242

Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents
Abstract Number: 1745

Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].